Peer review reports
From: Use of rituximab as an induction therapy in anti-glomerular basement-membrane disease
Original Submission | ||
---|---|---|
23 Sep 2017 | Submitted | Original manuscript |
23 Oct 2017 | Author responded | Author comments - Giovanna Clavarino |
Resubmission - Version 2 | ||
23 Oct 2017 | Submitted | Manuscript version 2 |
1 Apr 2018 | Reviewed | Reviewer Report - Wilfor Aguirre Quispe |
4 Apr 2018 | Reviewed | Reviewer Report - Jesper Bech |
21 Apr 2018 | Reviewed | Reviewer Report - Sirirat Anutrakulchai |
17 May 2018 | Author responded | Author comments - Giovanna Clavarino |
Resubmission - Version 3 | ||
17 May 2018 | Submitted | Manuscript version 3 |
25 Jul 2018 | Reviewed | Reviewer Report - Jesper Bech |
29 Jul 2018 | Reviewed | Reviewer Report - Sirirat Anutrakulchai |
1 Aug 2018 | Author responded | Author comments - Morgane Heitz |
Resubmission - Version 4 | ||
1 Aug 2018 | Submitted | Manuscript version 4 |
6 Sep 2018 | Author responded | Author comments - Morgane Heitz |
Resubmission - Version 5 | ||
6 Sep 2018 | Submitted | Manuscript version 5 |
7 Sep 2018 | Author responded | Author comments - Morgane Heitz |
Resubmission - Version 6 | ||
7 Sep 2018 | Submitted | Manuscript version 6 |
Publishing | ||
10 Sep 2018 | Editorially accepted | |
20 Sep 2018 | Article published | 10.1186/s12882-018-1038-7 |